About Nexigen

About company

Nexigen GmbH develops medicines to address high unmet clinical needs in oncology. Its NexiScreen screening technology identifies disease-relevant protein-protein interactions, as well as applies to various classes of intractable drug target proteins; and detects target interacting peptides (NexiTides) where common peptide interaction screening technologies can fail.